Categorized | Lactose in the News

Glomedics to distribute Biohit Lactose Intolerance Fast Test in… – ForexTV. com

Biohit Oyj Pr release September 2, 2016 at goal: 00 pm local time (EEST)

Biohit Oyj and Glomedics have agreed upon an agreement for the distribution of the Biohit Lactose Intolerance Quick Test in Southern Korea.

Lactose Intolerance Quick Test (LIQT) produced by Biohit allows the diagnosis of lactic intolerance from biopsy specimen. Lactose intolerance refers to the inability to digest lactose, the particular sugar present in milk. A normal little intestine produces lactase enzyme that catalyses hydrolysis of lactose directly into glucose and galactose for regular digestion. In people with lactase insufficiency, undigested lactose causes gastrointestinal difficulties, e. g. abdominal bloating plus cramps, flatulence, diarrhoea, nausea, or even vomiting.

In endoscopy-referred patients, a biopsy from the upper part of the small intestinal tract can be taken simultaneously for lactose intolerance testing. Biohit LIQT detects in 20 minutes, whether or not the lactase chemical is present in the biopsy specimen. Biohit LIQT has been shown to have a superior level of sensitivity compared to competing methods, such as the hydrogen breath test (HBT)*.

CEO C. G. Chung., Glomedics: ‘It is our own honour to be partner with Biohit Oyj and to distribute Lactose Intolerance Quick Test that is more unique, convenient plus accurate than other diagnostic tests. I am confident of the Lactose Intolerance Quick Test and sure that it will be the gold standard and routine test regarding patients with suspected lactose intolerance in Korea. We have started the sign up in Korea required to obtain the marketing authorisation for the test. ’

CEO Partial Korpela, Biohit Oyj: ‘In Korea there is a promising market for the Lactose Intolerance Quick Test. It is estimated that 90% of Asians suffer from lactose intolerance, which, however , frequently continues to be undiagnosed and untreated for years . ’

* Ojetti V, La Mura R et al., Dig Dis Sci 2008; 53(6): 1589-92

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor. relations@biohit. fi

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission can be “Innovating for Health” – all of us produce innovative products and services to promote study and early diagnosis. Biohit will be headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group.

Glomedics in brief

Glomedics is a analysis company headquartered in Goyang, Korea. Glomedics has a long-term and skilled sales network in gastrointestinal diagnostics market. The company has distributed useful disease diagnostics products for two decades in Korea. Glomedics has nicely long-term relationships with most of the Korean University Hospitals.

View original article:

Glomedics to distribute Biohit Lactose Intolerance Quick Test in South Korea

Be Sociable, Share!

    Leave a Reply

    Recent Posts

    My Experience